Avid Bioservices Inc. (NASDAQ:CDMOP) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avid Bioservices Inc.	36.53M	6.35	23.90M	-0.55	0.00
VistaGen Therapeutics Inc.	N/A	0.00	24.06M	-0.94	0.00

In table 1 we can see Avid Bioservices Inc. and VistaGen Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Avid Bioservices Inc. and VistaGen Therapeutics Inc.

	Net Margins	Return on Equity	Return on Assets
Avid Bioservices Inc.	-65.43%	0%	0%
VistaGen Therapeutics Inc.	0.00%	-328.5%	-187.7%

Institutional & Insider Ownership

Institutional investors owned 0.72% of Avid Bioservices Inc. shares and 11.6% of VistaGen Therapeutics Inc. shares. Avid Bioservices Inc.’s share owned by insiders are 7.06%. Comparatively, insiders own roughly 2.47% of VistaGen Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Avid Bioservices Inc.	2.36%	-1.91%	-4.46%	0.36%	5.4%	3.2%
VistaGen Therapeutics Inc.	-1.67%	-14.49%	28.26%	24.65%	-12.81%	58.97%

For the past year Avid Bioservices Inc. has weaker performance than VistaGen Therapeutics Inc.

Summary

On 6 of the 9 factors Avid Bioservices Inc. beats VistaGen Therapeutics Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.